Latest News
UK Biotech Venture Capital Nears a Record Year as Seed Funding Shrinks
UK biotech venture capital reached £2.84 billion in the first nine months of 2026. That is more than in any full year from 2022 to 2025. The figures come from the BioIndustry Association (BIA) Q3 2026 financing report, published on 26 October 2026 [1]. The BIA puts...
Latest News
Clinical Trials Roundup | 11 Sept 2026
Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...
Most Favoured Nation Pricing: What 26 Company Agreements Actually Commit To
Most favoured nation pricing is now the central instrument of United States drug pricing policy. On 31 August 2026, the White House announced agreements with nine further manufacturers. That brought the administration’s stated total to 26 companies, covering 89 per...
Partial Clinical Hold Lands on Opakalim Before SK Deal Closes
The US Food and Drug Administration has imposed a partial clinical hold on Biohaven’s epilepsy candidate opakalim. The hold took effect on 4 September 2026. Biohaven disclosed it in a Form 8-K filed on 10 September 2026. The measure stops new enrolment across the...
The Other Half of Innovation
What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
The Rising Reach of Black-Market Prescription Drugs in the UK
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
The Human Microbiome: An Interface Between Lifestyle, Metabolism & Health
For much of modern medicine, microorganisms have been largely viewed through a narrow lens, as agents of infection to be identified and then eliminated. This perspective, whilst undeniably important, captures only part of the story. Over the past two decades, advances...
How Behavioral Science and Machine Learning Can Transform Trial Adherence
It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...
Weekly News Roundup | 13 April 2026
Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...
The Gut Microbiome and the Future of Human Health
The gut microbiome has moved from a niche area of research to one of the most important frontiers in modern medicine. Once associated mainly with digestion, it is now understood to be a complex, organ-like system that influences immunity, metabolism and even brain...
Clinical Trials Roundup | 10 April 2026
Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...
The FDA PMTA Roundtable: Initial Reflections
Product characterisation remains the critical test of submission strength The US Food and Drug Administration (FDA) convened a roundtable on the Premarket Tobacco Product Application (PMTA) process, bringing together discussions on product characterisation,...
Beyond the Tumour: Can Radiotherapy Boost the Immune System?
Emerging research from a team of oncologists in Prague suggests that radiotherapy — long understood as a tool for destroying cancer cells — may also play a powerful role in activating the body's own immune defences. The implications for how we sequence and combine...
The Hidden ‘Perfect Healing’ Codes Within Your Body Have Been Deciphered
An axolotl loses its leg to a predator. Four weeks later, it has a functional replacement bones, nerves, muscles, and skin are perfectly re-formed. It is a biological masterpiece that has fascinated science for centuries. For decades, the prevailing dogma in...
Closing the Interventional Gap
The National Health Service (NHS) is investing heavily in diagnostics. Through Getting it Right First Time (GIRFT) and the rollout of Community Diagnostic Centres (CDCs), millions of patients are getting scans more quickly than ever[1]. The NHS 10 Year Plan has now...
Weekly News Roundup | 6 April 2026
Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...
Transforming Clinical Outsourcing: From Reactive to Predictive Strategy
The Growing Strain on Clinical Trial Operations Clinical trials have become increasingly diverse, complex, and expensive over the past decade. As the industry moves toward a more globalized model, managing timelines, coordinating across clinical functions, and...
The Rising Reach of Black-Market Prescription Drugs in the UK
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
The Human Microbiome: An Interface Between Lifestyle, Metabolism & Health
For much of modern medicine, microorganisms have been largely viewed through a narrow lens, as agents of infection to be identified and then eliminated. This perspective, whilst undeniably important, captures only part of the story. Over the past two decades, advances...
How Behavioral Science and Machine Learning Can Transform Trial Adherence
It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...
Weekly News Roundup | 13 April 2026
Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...
The Gut Microbiome and the Future of Human Health
The gut microbiome has moved from a niche area of research to one of the most important frontiers in modern medicine. Once associated mainly with digestion, it is now understood to be a complex, organ-like system that influences immunity, metabolism and even brain...
Clinical Trials Roundup | 10 April 2026
Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...
The FDA PMTA Roundtable: Initial Reflections
Product characterisation remains the critical test of submission strength The US Food and Drug Administration (FDA) convened a roundtable on the Premarket Tobacco Product Application (PMTA) process, bringing together discussions on product characterisation,...
Beyond the Tumour: Can Radiotherapy Boost the Immune System?
Emerging research from a team of oncologists in Prague suggests that radiotherapy — long understood as a tool for destroying cancer cells — may also play a powerful role in activating the body's own immune defences. The implications for how we sequence and combine...
The Hidden ‘Perfect Healing’ Codes Within Your Body Have Been Deciphered
An axolotl loses its leg to a predator. Four weeks later, it has a functional replacement bones, nerves, muscles, and skin are perfectly re-formed. It is a biological masterpiece that has fascinated science for centuries. For decades, the prevailing dogma in...
Closing the Interventional Gap
The National Health Service (NHS) is investing heavily in diagnostics. Through Getting it Right First Time (GIRFT) and the rollout of Community Diagnostic Centres (CDCs), millions of patients are getting scans more quickly than ever[1]. The NHS 10 Year Plan has now...
Weekly News Roundup | 6 April 2026
Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...
Transforming Clinical Outsourcing: From Reactive to Predictive Strategy
The Growing Strain on Clinical Trial Operations Clinical trials have become increasingly diverse, complex, and expensive over the past decade. As the industry moves toward a more globalized model, managing timelines, coordinating across clinical functions, and...
Featured Articles
Further News
Natural Diamonds in Healthcare
When we say "diamonds," most people think of a luxurious necklace or a super sparkly ring. A research lab would be the last place people imagine them being used. Interestingly, natural diamonds are getting a lot of attention in science and healthcare research. And...
Clinical Trials Roundup | 03 April 2026
Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...
Erectile Dysfunction is Preventable – if You Act Early
Did you know that your erections can tell you more about your heart health than you might think? Nocturnal erections—those spontaneous erections that happen during sleep—are directly tied to vascular health. When a man stops having them, even for a short period of...
Rethinking Lifestyle Diseases: From Risk Factors to Root Causes
Are we mistaking associations for true biological origins? Despite significant advances in modern medicine, lifestyle diseases such as cardiovascular disease and diabetes continue to rise globally. These conditions are commonly described as “multifactorial,”...
Rethinking Commercial Strategy for Late Biopharma Entrants
Being first to market in a new therapeutic class is often seen as a winning formula in biopharma. In reality, many of the biggest commercial successes come second, or even later. The difference is not luck. It is timing, differentiation and scale. Understanding late...
Python Blood Molecule Opens Door to New Obesity Treatments
Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...
Weekly News Roundup | 30 March 2026
Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...
International Menopause Society Unveils Global Care Framework
International Menopause Society sets new global standards for menopause care with evidence-led framework For the first time in a decade, the International Menopause Society (IMS) has released a complete redevelopment of its global menopause recommendations. Grounded...
Clinical Trials Roundup | 27 March 2026
An RNA therapy that preserves muscle while cutting visceral fat, a first in class oral non incretin obesity pill, late stage lung cancer portfolio data, NK cell immunotherapy in Alzheimer’s disease, and the first human trial of a cellular rejuvenation medicine...
New Report Highlights Why CGTs Still Struggle at Market Access
Cell and gene therapies are approved — so why aren’t they reaching patients? New industry report warns access systems — not science — are now the primary bottleneck A new report from Phacilitate argues that the biggest threat to cell and gene therapy (CGT) expansion...
The Radical Longevity Science Frontier
For decades, longevity has been a frontier of scientific exploration, pushing the boundaries of what we believe is possible for human health and lifespan. While incremental progress has been made in understanding the biology of aging, we are now on the cusp of a new...
Key Thoughts from the on! PLUS TPL Review
The evolving PMTA landscape for nicotine pouches The recent FDA authorisation of on! PLUS nicotine pouches is a significant moment in helping meet tobacco harm reduction (THR) goals. They are the first products to pass a new, faster FDA programme, signifying a...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.